Clinical Trials Logo

Clinical Trial Summary

Experimental intervention: electrocardiography. Control intervention: none

Duration of intervention per patient/subject:

5 min, observation 6 months

Key inclusion criteria:

- outpatients after lung transplantation (single, double or combined)

- outpatients on the wait list for lung transplantation

Key exclusion criteria:

• no informed consent


Clinical Trial Description

Primary endpoint:

• prevalence of significant QTc-interval prolongation (500 msec or above) after lung transplantation

Key secondary endpoint(s):

- prevalence of any QTc-interval prolongation (>440 msec ) after lung transplantation

- prevalence of PQ prolongation (200 msec sec or above) after lung transplantation

- prevalence of QRS prolongation (120 msec or above) after lung transplantation

- prevalence of QTc-prolonging drugs in drug regimen before and after lung transplantation

- influence of long-term neo-macrolide (e.g. azithromycin) on QTc interval after lung transplantation

- intra-individual difference of QTc interval before and after lung transplantation

- incidence of any QTc-interval prolongation(>440 msec ) after lung transplantation

- incidence of any QTc-interval prolongation (>440 msec or increase by 50msec or above) after initiation of new QTc prolonging drugs (especially neo-macrolides)

- reversal of QTc-interval prolongation (440 msec or lower or decrease by 50msec or above) after stopping any QTc prolonging drug

- Assessment of safety:

- Incidence of new onset heart rhythm disorder during 6 months of follow-up ;


Study Design

Observational Model: Cohort, Time Perspective: Prospective


Related Conditions & MeSH terms


NCT number NCT02380365
Study type Observational
Source Hannover Medical School
Contact Susanne Hoyer, MD
Phone 00495115324601
Email hoyer.susanne@mh-hannover.de
Status Not yet recruiting
Phase N/A
Start date April 2015
Completion date July 2016

See also
  Status Clinical Trial Phase
Completed NCT02744872 - Copenhagen Acute Renal Complications After Transplantations Study Group Phase 4
Completed NCT01915082 - Peri-operative Azithromycin to Improve Early Allograft Function and Outcome After Lung Transplantation Phase 4
Withdrawn NCT02395393 - Confocal Fluorescence Microscopy of the Human Airways in Diagnostics of Lung Transplantation N/A
Completed NCT02262299 - European Trial of Pirfenidone in BOS, A European Multi-center Study Phase 2/Phase 3
Withdrawn NCT04415476 - Standard Therapy Using Tacrolimus, Mycophenolate Mofetil and Prednisone For Chronic Lung Transplant Rejection (BOS) Phase 2
Completed NCT01650545 - Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients Phase 1/Phase 2
Completed NCT01746914 - Morphofunctional Lung Analysis by PET and CT After Lung Transplantation N/A
Completed NCT01967953 - Ex-Vivo Lung Perfusion to Increase the Number of Organs for Transplantation Phase 1
Completed NCT02363959 - Hyperbaric Oxygen Therapy for Lung Transplantation Phase 2
Completed NCT01793246 - Registry Trial to Determine pCLE Image Interpretation Criteria and Preliminary Accuracy in the Lung N/A
Recruiting NCT00177918 - Prospective Evaluations of Infectious Complication in Lung Transplant Recipients
Terminated NCT03473340 - Studying the Treatment Effect of Pirfenidone in Chronic Lung Allograft Dysfunction (STOP-CLAD) Phase 2